Neoantigens in Chronic Obstructive Pulmonary Disease and Lung Cancer: A Point of View. Issue 2 (11th February 2019)

• Record Type: Journal Article
• Authors: Zeneyedpour, Lona; Dekker, Lennard J. M.; van Sten‐van`t Hoff, Jenny J. M.; Burgers, Peter C.; ten Hacken, Nick H. T.; Luider, Theo M.
• Other Names: Frantzi Maria guestEditor.; Mischak Harald guestEditor.; Latosinska Agnieszka guestEditor.
• Is Part Of: Proteomics. Volume 13:Issue 2(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-02-11
• Subjects: COPD -- lung cancer -- neoantigens; Proteomics -- Periodicals; 572.605
• DOI: 10.1002/prca.201800093
• Languages: English
• ISSNs: 1862-8346

Abstract

Abstract: The goal of this manuscript is to explore the role of clinical proteomics for detecting mutations in chronic obstructive pulmonary disease (COPD) and lung cancer by mass spectrometry‐based technology. COPD and lung cancer caused by smoke inhalation are most likely linked by challenging the immune system via partly shared pathways. Genome‐wide association studies have identified several single nucleotide polymorphisms which predispose an increased susceptibility to COPD and lung cancer. In lung cancer, this leads to coding mutations in the affected tissues, development of neoantigens, and different functionality and abundance of proteins in specific pathways. If a similar reasoning can also be applied in COPD will be discussed. The technology of mass spectrometry has developed into an advanced technology for proteome research detecting mutated peptides or proteins and finding relevant molecular mechanisms that will enable predicting the response to immunotherapy in COPD and lung cancer patients.